FDA Warns 30 Telehealth Firms Over Misleading GLP-1 Claims
TL;DR
The FDA issued 30 warning letters to telehealth companies for misleading marketing of compounded GLP-1 products, the second wave in a crackdown on direct-to-consumer pharmaceutical ads. The letters allege claims of sameness with FDA-approved products and branding that obscures sourcing. Compounded drugs are not FDA-approved and are not the same as generics, as the FDA does not review their safety or efficacy before marketing.
- FDA Warns 30 Telehealth Companies Against Illegal Marketing of Compounded GLP-1s fda.gov
- FDA sends warning to 30 telehealth companies selling ‘illegal’ GLP-1s The Hill
- Hims & Hers back in red as FDA doubles down on GLP-1 compounders Seeking Alpha
- US FDA warns 30 telehealth firms over misleading marketing of compounded GLP‑1 drugs Yahoo
- US FDA warns 30 telehealth firms over misleading ads for compounded weight‑loss drugs Reuters
Want the full story? Read the original reporting
Read on fda.gov